Leadership

Management Team

Michael S. Anderson
Chief Executive Officer
Michael S. Anderson was appointed Chief Executive Officer of Flamel Technologies in March 2012. Previously, Anderson was the President and Chief Executive Officer of Éclat Pharmaceuticals, L.L.C., a specialty pharma company located in St. Louis, Missouri. Éclat, which began operation in November 2010, was acquired by Flamel in March of this year. Prior to Eclat, Anderson was at KV Pharmaceutical Company, where he served as President and CEO of its generic business, ETHEX Corporation, and was also the President and CEO of Ther-Rx Corporation, a leader in women’s healthcare. He also was with Schein Pharmaceutical and started his career with A.H. Robins Company.
Sandy Hatten
Senior Vice President of Quality and Regulatory Affairs
Ms. Hatten has over 30 years’ experience and held a number of senior leadership roles in Quality spanning manufacturing, drug development and drug applications of branded and generic pharmaceuticals, quality assurance and quality control, and regulatory functions, at companies such as Mallinckrodt, KV Pharmaceuticals, Catalent Pharma Solutions and Perrigo. Ms. Hatten holds a M.A. and B.A from Marshall University.
Phillandas T. Thompson, J.D., M.B.A.
Senior Vice President, General Counsel and Corporate Secretary
Mr. Thompson was appointed Senior Vice President, General Counsel in November 2013. Previously, he served as Vice President, Legal Affairs at West-Ward Pharmaceutical Corp. (2012-2013), Vice President, General Counsel at Paddock Laboratories, Inc. (2010-2012), Vice President, Strategic Business Transactions and Assistant General Counsel at KV Pharmaceutical (2006-2010), Associate General Counsel and Assistant Secretary at Barr Pharmaceutical (2002-2006), and Corporate Associate at White & Case LLP (1998-2002). Mr. Thompson is a member of the New York Bar, the Missouri Bar, and the Minnesota Bar and has several other professional affiliations. Mr. Thompson earned a B.A. from Washington University in St. Louis and is also a graduate of the University of Michigan Law School (Juris Doctor) and the University of Michigan Business School (Master of Business Administration).
Mike Kanan
Senior Vice President and Chief Financial Officer
Mr. Kanan brings 30 years of finance experience to Flamel. He began his career at Deloitte & Touche, where he spent eleven years serving clients such as The Dow Chemical Company and General Motors. Following Deloitte, Mr. Kanan joined the Hutchinson Group, a subsidiary of Total S.A., where he quickly rose to become CFO of Hutchinson Sealing Systems. In 2001, he joined ArvinMeritor, a Fortune 500 global automotive and heavy truck systems company with $7 billion in revenue, in various finance leadership roles. Mr. Kanan joined Sigma-Aldrich in 2009 where reached the position of Vice President Finance, Corporate Controller and Chief Accounting Officer. Mr. Kanan holds a Bachelor of Arts degree in Accounting from Michigan State University and became a CPA in 1987.
Gregory J. Davis
Vice President of Corporate and Business Development
Mr. Davis spent eight years as the Director of Worldwide Business Development at GlaxoSmithKline and more recently has held positions as Vice President of Corporate Development for Patheon and Chief Business Officer of Flag Therapeutics, a company which he also co-founded. Throughout his career, Mr. Davis has led and negotiated a substantial number of large transactions, including acquisitions of products and businesses as well as licensing agreements. Mr. Davis holds a B.A. in Economics from the University of North Carolina, Chapel Hill and an M.B.A from Keenan Flagler Business School.
David Monteith, Ph.D.
Vice President of Research and Development
Dr. Monteith has over 25 years’ experience working in the pharmaceutical and drug delivery industry, mostly in senior leadership roles. He has worked for several pharmaceutical companies including Syntex, Merck-Lipha, Schering Plough and most recently Merck & Co. Inc. Dr. Monteith is a graduate in Pharmacy from the University of Strathclyde, Glasgow where he also obtained his PhD from the Department of Pharmaceutics. He later also received a MBA from the University of Warwick, UK. David has held several positions of increasing responsibility in the industry and has spent the last 14 years in the USA with Schering-Plough and Merck. David has concentrated most of his career in the areas of drug delivery and pharmaceutical drug product development and he most recently served as Associate Vice President of Pharmaceutical Development for Emerging Markets at Merck.
Dhiren D’Silva
Vice President of Irish and European Operations
Mr. D’Silva has 20 years of pharmaceutical experience with an extensive background in business development, general management and business operations in the US, Europe and Asia. Most recently, he held the position of Senior Director of International Business Operations at NPS Pharma (now Shire). In that role, Dhiren established NPS’s international operations and infrastructure out of Ireland. Prior to joining NPS, Dhiren worked for Catalent Pharma Solutions in Somerset (New Jersey), a leading drug delivery provider as Director of Business Development, Product Ventures Group focusing on the development and out licensing of ANDA’s and 505b2’s.
Dhiren started his career at Strides Arcolab, a multinational pharmaceutical company, as Associate General Manager in Bangalore (India), then as Vice President, Commercial in Somerset, New Jersey. He holds a MBA from the Katholieke Universiteit Lewen (Belgium) as well as a BA in Economics from the St-Xavier College in Bombay (India).

Board of Directors

The Honorable Craig R. Stapleton
Chairman
Former United States Ambassador to France, Senior Advisor to Stone Point Capital, Director of Abercrombie & Fitch Co., former President of Marsh and McLennan Real Estate Advisors of New York, President of the Vaclav Havel Foundation in the United States, member of the Board of Directors of the George W. Bush Library and Foundation and of the National September 11 Memorial and Museum at the World Trade Center
Michael S. Anderson
Director
Chief Executive Officer of Flamel Technologies
Guillaume Cerutti
Director
Chairman and CEO of Sotheby’s France
Francis J.T. Fildes, Ph.D.
Director
Former Senior Vice President: Head of Global Development for AstraZeneca, PLC, Director of ProStrakan Group PLC and Fildes Partners Ltd, and a Fellow of the Royal Society of Medicine and the Royal Society of Chemistry
Christophe Navarre
Director
President and CEO of Moët-Hennessy (the Wine and Spirits division of LVMH), Board Member of the Comité Colbert, Member of the HEINEKEN Supervisory Board and Chairman of the FEVS (Fédération des Exportateurs de Vins et Spiritueux), Officer of the Legion of Honour (France), Commander of the Order of Agricultural Merit (France), Commander of the Order of Leopold II (Belgium) and Officer of the Royal Order of the Crown of Belgium
Ben C. Van Assche
Director
Executive Chairman Armonea, Chairman of the Board of Bone Therapeutis, Member Of The Supervisory Board at Punch Graphix plc, former CEO of Xeikon, former chairman of Essenscia, global assignments in large and mid-size companies such as Cytec, UCB, Alcon and Baxter